VA awards McKesson Corporation $999.99M for FY2025 Pharmaceutical Prime Vendor services in Texas

Contract Overview

Contract Amount: $999,993,461 ($1000.0M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-03-01

End Date: 2025-03-31

Contract Duration: 30 days

Daily Burn Rate: $33.3M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MARCH

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $1000.0 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MARCH Key points: 1. Contract value represents a significant portion of annual pharmaceutical spending for the VA. 2. The firm fixed-price contract type aims to control costs and provide predictable spending. 3. The single delivery order covers one month of services, suggesting a recurring need. 4. McKesson Corporation is a major player in pharmaceutical distribution, indicating established market presence. 5. The contract's duration is short, implying potential for future re-competition or adjustments. 6. Geographic focus on Texas may indicate regional demand or specific VA facility needs.

Value Assessment

Rating: good

The contract value of approximately $1 billion for a single month of pharmaceutical prime vendor services is substantial. While direct comparisons for a one-month delivery order are difficult, the annual spending on such services can be in the tens of billions. The firm fixed-price structure is a standard approach for managing costs in this sector. Benchmarking the per-unit cost of pharmaceuticals procured through this vendor would provide a clearer picture of value for money, but the overall scale suggests significant volume discounts are likely being leveraged.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple vendors were eligible to bid. The specific number of bidders is not provided, but the 'full and open' designation suggests a competitive process was undertaken. This approach is generally expected to yield competitive pricing and a wider range of solutions.

Taxpayer Impact: Taxpayers benefit from a competitive process that should drive down costs and ensure the VA receives the best possible pricing for essential pharmaceutical supplies.

Public Impact

Veterans in Texas will benefit from timely access to a wide range of pharmaceuticals. The contract ensures the continuous supply of medications to VA healthcare facilities. This supports the operational readiness of VA medical centers and clinics within the specified region. The contract indirectly supports jobs within the pharmaceutical supply chain and logistics sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases in future contract periods if competition diminishes.
Dependence on a single vendor for a critical supply chain component carries inherent risk.
The short duration of this delivery order may indicate a need for more long-term strategic planning.

Positive Signals

Awarded through full and open competition, suggesting a robust bidding process.
Firm fixed-price contract provides cost certainty for the VA.
McKesson Corporation's established presence suggests reliability in supply chain management.

Sector Analysis

The pharmaceutical prime vendor market is a critical component of the healthcare sector, ensuring the availability of medications to government agencies and healthcare providers. This contract falls within the broader pharmaceutical preparation manufacturing and distribution industry. Spending in this area is consistently high due to the essential nature of pharmaceuticals. Comparable contracts exist across various federal agencies, including the Department of Defense and other health-focused entities, often involving multi-billion dollar annual commitments.

Small Business Impact

The provided data does not indicate any specific small business set-aside provisions for this contract. As a large prime vendor contract, it is unlikely to directly benefit small businesses unless they are subcontractors to McKesson Corporation. Further analysis would be needed to determine the extent of small business subcontracting opportunities associated with this award.

Oversight & Accountability

The Department of Veterans Affairs has established oversight mechanisms for its contracting processes, including this pharmaceutical prime vendor contract. Accountability is typically managed through contract performance monitoring, regular reporting requirements, and adherence to the terms and conditions of the firm fixed-price agreement. Transparency is facilitated through public contract databases where such awards are reported. The VA Office of Inspector General may conduct audits or investigations if performance issues or potential fraud are identified.

Related Government Programs

Pharmaceutical Prime Vendor Program
Department of Veterans Affairs Medical Supplies Contracts
Federal Supply Schedule (FSS) Pharmaceutical Contracts
Defense Logistics Agency (DLA) Troop Support Medical Prime Vendor Program

Risk Flags

Potential for price increases in future contract periods if competition diminishes.
Dependence on a single vendor for a critical supply chain component carries inherent risk.
The short duration of this delivery order may indicate a need for more long-term strategic planning.

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1000.0 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MARCH

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1000.0 million.

What is the period of performance?

Start: 2025-03-01. End: 2025-03-31.

What is McKesson Corporation's track record with the VA for pharmaceutical prime vendor services?

McKesson Corporation has a long-standing relationship with the Department of Veterans Affairs as a pharmaceutical prime vendor. They are one of the major distributors awarded contracts under the VA's Pharmaceutical Prime Vendor (PPV) program, which has been in place for many years. Historical data indicates McKesson has consistently secured significant portions of this contract vehicle, reflecting their substantial market share and established infrastructure. While specific performance metrics for past contracts are not detailed here, their continued success in winning these large-scale awards suggests a generally satisfactory performance history in terms of delivery, product availability, and compliance with VA requirements. However, like any large-scale vendor, there may have been isolated incidents or reviews of specific performance aspects over the years that would require deeper investigation into VA contract performance databases.

How does the value of this single delivery order compare to the VA's overall annual pharmaceutical spending?

This single delivery order for McKesson Corporation is valued at approximately $999.99 million, representing a substantial amount for a one-month period. The VA's total annual pharmaceutical spending is significantly higher, often reaching tens of billions of dollars. This delivery order likely represents a portion of the total monthly or quarterly allocation for pharmaceutical prime vendor services. The VA procures pharmaceuticals through various channels, including prime vendors, the Federal Supply Schedule (FSS), and direct manufacturer contracts. Therefore, while this $1 billion delivery order is a large sum, it is part of a much larger, complex ecosystem of pharmaceutical procurement designed to meet the diverse needs of millions of veterans across the country.

What are the primary risks associated with relying on a single prime vendor for pharmaceutical distribution in a specific region?

Relying on a single prime vendor like McKesson Corporation for pharmaceutical distribution in Texas presents several risks. Firstly, there is a risk of supply chain disruption due to unforeseen events such as natural disasters, labor strikes, or logistical failures affecting the vendor's operations. Secondly, a lack of robust competition for subsequent contract periods could lead to price escalations, reducing the overall value for money. Thirdly, over-reliance on one vendor might stifle innovation and the adoption of new distribution technologies or services. Finally, if the vendor experiences financial instability or significant compliance issues, it could lead to critical shortages of essential medications for veterans in the region, impacting healthcare delivery.

What does the 'full and open competition' designation imply about the pricing and efficiency of this contract?

The 'full and open competition' designation for this contract implies that the Department of Veterans Affairs actively sought bids from all responsible sources, without restrictions. This process is designed to foster a competitive environment where multiple vendors can present their proposals, including pricing, technical capabilities, and past performance. In theory, this should lead to the most advantageous pricing for the government, as vendors compete to win the contract. It suggests that the VA has a reasonable expectation that the pricing secured through this method is efficient and reflects market conditions. However, the actual efficiency and value are also dependent on the specific evaluation criteria used and the number of serious bidders that participated in the process.

How does the firm fixed-price contract type benefit the VA in managing pharmaceutical expenditures?

A firm fixed-price (FFP) contract type is highly beneficial for the VA in managing pharmaceutical expenditures because it establishes a ceiling on the total cost of the contract. Under an FFP agreement, the contractor, McKesson Corporation, is obligated to perform the work and deliver the pharmaceuticals for the agreed-upon price, regardless of their actual costs. This shifts the risk of cost overruns from the government to the contractor. For the VA, this provides significant budget certainty and predictability, making it easier to forecast and manage its pharmaceutical spending. It incentivizes the contractor to control its own costs efficiently to maximize profit, which can indirectly benefit the government through competitive pricing during the bidding process.

What is the significance of the short contract duration (30 days) for this delivery order?

The short duration of this delivery order, specified as 30 days, is significant and suggests several possibilities. It could indicate that this is a routine, recurring need that is fulfilled through a series of short-term delivery orders against a larger indefinite-delivery/indefinite-quantity (IDIQ) contract or a similar overarching agreement. Alternatively, it might represent a bridge contract to cover a gap while a longer-term contract is being finalized or re-competed. It could also be a mechanism to allow for flexibility in adjusting quantities or specific product needs on a monthly basis based on fluctuating demand or inventory levels. Without more context on the overarching contract vehicle, it's difficult to pinpoint the exact strategic reason, but it implies a dynamic or short-term fulfillment requirement.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $999,993,461

Exercised Options: $999,993,461

Current Obligation: $999,993,461

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline